**Core Concept:** Nasiritide is a synthetic analog of human atrial natriuretic peptide (ANP), a hormone released in response to increased blood volume or pressure. Its primary actions include natriuresis (sodium excretion) and vasodilation, which can be beneficial in treating congestive heart failure (CHF) and volume overload conditions.

**Why the Correct Answer is Right:** Nasiritide has a short half-life (approximately 5 minutes) due to rapid degradation by neutral endopeptidase (NEP). This short half-life limits its clinical application, as it necessitates frequent administration for sustained therapeutic effect.

**Why Each Wrong Option is Incorrect:**

A. Nasiritide is a long-acting drug (incorrect): The correct answer states that its half-life is short, not long.
B. Nasiritide has no significant side effects (incorrect): Nasiritide can cause hypotension, and its short half-life and rapid degradation make it unsuitable for long-term therapy.
C. Nasiritide is a selective vasodilator (incorrect): Although it does cause vasodilation, its actions extend beyond just vasodilation, including natriuresis and other effects.
D. Nasiritide is used to treat hypertension (incorrect): Nasiritide is primarily used in the context of congestive heart failure (CHF) and volume overload conditions, not hypertension.

**Clinical Pearl:** The correct answer highlights the limitations of nasiritide due to its short half-life and potential side effects. While it may have some therapeutic benefits, its rapid degradation makes it unsuitable for long-term treatment and requires frequent administration. This emphasizes the importance of considering the patient's specific clinical context and drug alternatives when making treatment decisions.